Track topics on Twitter Track topics that are important to you
Relvar Ellipta (FF/VI) is the first once-daily, inhaled corticosteroid/long-acting beta agonist (ICS/LABA) combination for the regular treatment of asthma in adults and adolescents aged 12 years and older approved in Japan. Relvar Ellipta contains the ICS fluticasone furoate (FF) and the LABA vilanterol (VI) and may be prescribed in two doses – 100/25 mcg and 200/25 mcg. Both dosages are administered using the Ellipta, a new dry powder inhaler (DPI).
For further information open http://www.gsk.com/